NatureCell Co.,Ltd.

A007390

KR7007390008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-06-30 EDT			5-day change	1st Jan Change
9,750 ^KRW	+4.06%		+1.46%	+22.03%

2023	NatureCell Co.,Ltd. announced that it has received KRW 5 billion in funding	CI
2023	NatureCell to Raise 5 Billion Won via Stock Sale	MT

R & L Natural Life Co., Ltd. acquired an additional 3.43% stake in Nature Cell Co.,Ltd. from Jeong-Chan Rah for KRW 1 billion.

April 03, 2013 at 12:00 am

R & L Natural Life Co., Ltd. acquired an additional 3.43% stake in Nature Cell Co.,Ltd. (KOSE:A007390) from Jeong-Chan Rah for KRW 1 billion on March 27, 2013. R & L Natural Life Co., Ltd. acquired 1 million shares of Nature Cell Co at KRW 1000 per share. Following the completion of the deal, R & L Natural Life Co., Ltd. holds 13.72% stake in Nature Cell Co., Ltd.

R & L Natural Life Co., Ltd. completed the acquisition of an additional 3.43% stake in Nature Cell Co.,Ltd. (KOSE:A007390) from Jeong-Chan Rah on March 27, 2013.

Latest news about NatureCell Co.,Ltd.

NatureCell Co.,Ltd. announced that it has received KRW 5 billion in funding	23-06-28	CI
NatureCell to Raise 5 Billion Won via Stock Sale	23-06-14	MT
NatureCell Co.,Ltd. announced that it expects to receive KRW 5 billion in funding	23-06-12	CI
NatureCell Co.,Ltd. announced that it has received KRW 11 billion in funding	23-05-09	CI
NatureCell to Raise 11 Billion Won in Stock Sale; Shares Rise 3%	23-05-01	MT
NatureCell Co.,Ltd. announced that it expects to receive KRW 11 billion in funding	23-05-01	CI
NatureCell Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
NatureCell Co.,Ltd. announced that it has received KRW 30 billion in funding	22-05-19	CI
NatureCell Co.,Ltd. announced that it expects to receive KRW 30 billion in funding	22-04-11	CI
R Bio Co.,Ltd. agreed to acquire 9.01% stake in NatureCell Co.,Ltd. from Biostar Korea Co., Ltd.	21-05-24	CI
NatureCell Co.,Ltd. announced that it has received KRW 10 billion in funding	20-08-25	CI
NatureCell Co.,Ltd. announced that it expects to receive KRW 10 billion in funding	20-08-23	CI
NatureCell Co.,Ltd. cancelled the acquisition of 2.3% stake in JASC Co., Ltd.	19-12-10	CI
NatureCell Co.,Ltd. agreed to acquire additional 2.3% stake in JASC Co., Ltd. for KRW 1.8 billion.	18-12-11	CI
Nature Cell Starts Commercial Clinical Trials Phase I and II ‘ASTROSTEM,’ Stem Cell Drug for Alzheimer's Disease Treatment in U.S	17-03-10	CI
Nature Cell Co.,Ltd. Receives U.S. FDA Approval for Phase I and II Alzheimer's Clinical Trial	16-11-28	CI
NatureCell Co.,Ltd.(KOSDAQ:A007390) added to S&P Global BMI Index	16-09-19	CI
Nature Cell Co.,Ltd. announced that it has received KRW 5 billion in funding	16-07-19	CI
Nature Cell Co.,Ltd. announced that it expects to receive KRW 5 billion in funding	16-06-29	CI
Sejong Life Science Laboratory sold 0.09% stake in Nature Cell Co.,Ltd. for approximately KRW 230 million.	16-05-15	CI
An unknown buyer acquired 0.07% stake in Nature Cell Co.,Ltd. from Sejong Life Science Laboratory for approximately KRW 180 million.	16-05-15	CI
Biostar Korea Co., Ltd. acquired additional 8.9% stake in Nature Cell Co.,Ltd. from K-STECMCELL Co.,Ltd. for KRW 27 billion.	16-02-15	CI
R Bio Co.,Ltd. announced that it has received KRW 13 billion in funding from NatureCell Co.,Ltd.	15-07-21	CI
K-STECMCELL CO.,Ltd. announced that it expects to receive KRW 14.5 billion in funding from Nature Cell Co.,Ltd. and other investors.	15-07-19	CI
Nature Cell Co.,Ltd. announced that it has received KRW 2.3 billion in funding from New Pride Corporation.	15-03-12	CI

Chart NatureCell Co.,Ltd.

Duration

Period

More charts

Company Profile

NatureCell Co Ltd is a Korea-based company principally engaged in the stem cell business. The Company operates its business through three segments. The Stem Cell Business segment is engaged in the development of stem cell therapeutics, the manufacture of stem cell culture media, the development and sale of stem cell culture cosmetics, and the provision of blood cell storage services, among others. The Food Business segment is engaged in the manufacture and sale of fruit beverages including tomato juice, peach juice and others, canned beverages such as sikhye, fruit concentrates and others, as well as fermentation and health functional foods. The Hygiene Business segment is engaged in the manufacture and sale of health hygiene products such as masks, disinfectants, wipes, and others.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
NATURECELL CO.,LTD.	+22.03%	436M
CSL LIMITED	+1.92%	95.18B
SAMSUNG BIOLOGICS CO.,LTD.	-0.13%	37.55B
BIOGEN INC.	-10.43%	33.75B
UCB	+77.76%	28.2B
BIOMARIN PHARMACEUTICAL INC.	-14.82%	15.63B
INCYTE CORPORATION	-3.06%	13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.76%	11.5B
ALTEOGEN INC.	+181.73%	10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-53.92%	9.23B